HCM Presents Savolitinib Phase II Data Showing 32.3% ORR, 9.7 Months Median DoR in MET-Amplified Gastric Cancer at Upcoming ASCO Meeting
HUTCHMED (China) Limited American Depositary Shares · Now $11.40
-6.3% in 3d after detection
Post-detection moves
1h
0.0%
1d
-2.9%
3d
-6.3%
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS